Iliopoulou, Konstantina
Koufargyris, Panagiotis
Doulou, Sarantia
Tasouli, Elisavet
Katopodis, Sokratis
Chachali, Stavroula-Porphyria
Schinas, Georgios
Karachalios, Charalampos
Astriti, Myrto
Katsaounou, Paraskevi
Chrysos, George
Seferlis, Theodoros
Dimopoulou, Effrosyni
Kollia, Myrto
Poulakou, Garyphalia
Gerakari, Styliani
Papanikolaou, Ilias C.
Milionis, Haralampos
Dalekos, George N.
Tzavara, Vasiliki
Kontopoulou, Theano
Giamarellos-Bourboulis, Evangelos J. http://orcid.org/0000-0003-4713-3911
Funding for this research was provided by:
Hellenic Society for the Study of Sepsis
Boditech Inc, South Korea
Article History
Received: 7 November 2023
Accepted: 4 December 2023
First Online: 19 December 2023
Declarations
:
: Garyphalia. Poulakou has received honoraria and/or consulting fees by Astra-Zeneca, Gilead, GSK, Menarini, MSD, Norma, Pfizer and SOBI and research grants by the University of Minnesota/University College London, the Hellenic Institute for the Study of Sepsis, Bausch, Roche, Xenothera, FabNTech and Pfizer. Ilias C. Papanikolaou has received honoraria or served as PI for studies from Boehringer-Ingelheim, GlaxoSmithKline and AstraZeneca. Haralampos. Milionis reports receiving honoraria, consulting fees and non-financial support from healthcare companies, including Amgen, Angelini, Bayer, Mylan, MSD, Pfizer, and Servier. George N Dalekos is an advisor or lecturer for Pfizer, Roche, Sanofi and Sobi, and received research grants from Gilead and has served as PI in studies for Gilead, Novo Nordisk, Genkyotex, Regulus Therapeutics Inc, Tiziana Life Sciences, Bayer, Astellas, Pfizer, Amyndas Pharmaceuticals, CymaBay Therapeutics Inc., Sobi and Intercept Pharmaceuticals. Evangelos. J. Giamarellos-Bourboulis has received honoraria from Abbott Products Operations, bioMérieux, Brahms GmbH, GSK, InflaRx GmbH, Sobi and Xbiotech Inc; independent educational grants from Abbott Products Operations, bioMérieux Inc, InflaRx GmbH, Johnson & Johnson, MSD, Sobi and Xbiotech Inc.; and funding from the Horizon2020 Marie Skłodowska-Curie International Training Network “the European Sepsis Academy” (granted to the National and Kapodistrian University of Athens), the Horizon 2020 European Grants ImmunoSep and RISCinCOVID and the Horizon Health grant EPIC-CROWN-2 (granted to the Hellenic Institute for the Study of Sepsis). Konstantina Iliopoulou, Panagiotis Koufargyris, Sarantia Doulou, Elisavet Tasouli, Sokratis Katopodis, Stavroula-Porphyria Chachali, Georgios Schinas, Charalambos Karachalios, Myrto Astriti, Parakevi Katsaounou, George Chrysos, Theodors Seferlis, Effrosyni Dimopoulou, Myrto Kollia, Styliani Gerakari, Vasiliki Tzavara, and Theano Kontopoulou have no competing interests.
: The study is a sub-study part of the clinical trials ACCESS and ImmunoSep which were licensed by the National Ethics Committee of Greece (approvals 122/20 and 2/21) and the National Organization for Medicines of Greece (approvals IS113/20 and IS008/21) (ClinicalTrials.gov registrations NCT04724044 and NCT04990232). Written informed consent was provided by the patients or their legal representative. Patients who were screened for eligibility for both trials participated in the present study. The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.